Flucytosine primary resistance in Candida species and Cryptococcus neoformans

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 20, Issue 4, 2001, Pages 276-279

  Cuenca Estrella, M ^a   Diaz Guerra T M ^a   Mellado, E ^a   Rodriguez Tudela J L ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CRYPTOCOCCUS NEOFORMANS; FUNGUS CULTURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0035009787     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00011265     Document Type: Article

References (15)

1. Bennet JE: Flucytosine. Annals of Internal Medicine (1977) 86:319-322
2. Kauffman CA, Carver PL: Antifungal agents in the 1990s. Drugs (1997) 53:539-549
3. White TC, Marr KA, Bowden RA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clinical Microbiology Reviews (1998) 11:382-402
4. Viviani MA: Flucytosine - what is its future? Journal of Antimicrobial Chemotherapy (1995) 35:241-244
5. Barchiesi F, Arzeni D, Caselli F, Scalise G: Primary resistance to flucytosine among clinical isolates of Candida spp. Journal of Antimicrobial Chemotherapy (2000) 45:408-409
6. Iwata K: Drug resistance in human pathogenic fungi. European Journal of Epidemiology (1992) 8:407-421
7. Graybill JR: The future of antifungal therapy. Clinical Infectious Diseases (1996) 22, Supplement 5:166-178
8. Francis P, Walsh TA: Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clinical Infectious Diseases (1992) 15:1003-1018
9. Auger P, Dumas C, Joly J: A study of 666 strains of Candida albicans: correlation between serotype and susceptibility to 5-fluorocytosine. Journal of Infectious Diseases (1979) 139:590-594
10. Weber S, Polak A: Susceptibility of yeasts isolates from defined German patient groups to 5-fluorocytosine. Mycoses (1992) 35:163-171
11. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. NCCLS, Wayne, PA (1997)
12. Rodríguez-Tudela JL, Martínez-Suárez JV: Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrobial Agents and Chemotherapy (1994) 38:45-48
13. Rodriguez-Tudela JL, Martín-Díez F, Cuenca-Estrella M, Rodero L, Carpintero Y, Gorgojo B: Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose. Antimicrobial Agents and Chemotherapy (2000) 44:400-404
14. Brawner DL, Anderson GL, Yuen KY: Serotype prevalence of Candida albicans from blood culture isolates. Journal of Clinical Microbiology (1992) 30:149-153
15. Torssander J, Chryssanthou E, Petrini B: Increased prevalence of oral Candida albicans serotype B in homosexual men: a comparative and longitudinal study in HIV-infected and HIV-negative patients. Mycoses (1996) 39:353-356